Data from first-in-human Phase 1 study of arenaviral therapeutics, including first data on HB-201/HB-202 alternating 2-vector therapy and expanded data on HB-201, to be featured as oral presentation ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results